

XYLAZINE TEST STRIP

Immunoassay Performance Characteristics

RESULTS

Substance	10 µg/ml	100 µg/ml	500 µg/ml	1 mg/ml	5 mg/ml	10 mg/ml
Xylazine	POS	POS	POS	POS	POS	POS
Fentanyl	NEG	NEG	NEG	NEG	NEG	NEG
Methamphetamine	NEG	NEG	NEG	NEG	NEG	NEG
MDMA	NEG	NEG	NEG	NEG	NEG	NEG
Diphenhydramine	NEG	NEG	NEG	NEG	NEG	NEG
Phenacetin	NEG	NEG	NEG	NEG	NEG	NEG
Levamisole	NEG	NEG	NEG	POS	POS	POS
Lidocaine	NEG	NEG	NEG	NEG	NEG	NEG
Procaine	NEG	NEG	NEG	NEG	NEG	NEG
Quinine	NEG	NEG	NEG	NEG	NEG	NEG

CONCLUSION

The Xylazine Test Strip manufactured by W.H.P.M., Inc demonstrated no cross-reactivity with the illicit substances tested in this study including fentanyl, methamphetamine, and MDMA. The results indicate that the xylazine test strip evaluated is highly specific to xylazine detection when testing polysubstance compounds containing two or more of the listed illicit substances.

Of the six potentially cross-reacting substances/cutting agents tested, the xylazine test strip demonstrated cross-reactivity resulting in a false-positive results with Levamisole at concentrations of 1mg/ml or more. It should also be noted that Lidocaine at concentrations of 10 mg/ml did result in a weak test line that could be misinterpreted if the user is not careful. No cross-reactivity was observed when testing other common cutting agents including Diphenhydramine, Phenacetin, Procaine, and Quinine at concentrations up to 10 mg/ml in solution. The potential cross-reactivity observed with Levamisole may be problematic if samples are improperly prepared and the substance is present in relatively high concentrations. However, the observed cross-reactivity is unlikely to compromise the substance testing effectiveness of the xylazine test strip for detecting xylazine in solution when used within the recommended solution preparation concentration range of 2mg of substance/ml.

REFERENCES

1. FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs - <https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs>
2. Thangada S, Clinton HA, Ali S, et al. Notes from the field: Xylazine, a veterinary tranquilizer, identified as an emerging novel substance in drug overdose deaths - Connecticut, 2019-2020. *MMWR Morb Mortal Wkly Rep.* 2021;70(37):1303-1304. doi:10.15585/mmwr.mm7037a
3. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. *Drug Alcohol Depend.* 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
4. Anna Żubrycka, Andrzej Kwaśnica, Monika Hacziewicz, Karolina Sipa, Konrad Rudnicki, Sławomira Skrzypek, Lukasz Poltorak, Illicit drugs street samples and their cutting agents. The result of the GC-MS based profiling define the guidelines for sensors development, *Talanta*, Volume 237, 2022, 122904, ISSN 0039-9140, <https://doi.org/10.1016/j.talanta.2021.122904>.